Dr. Ryan H. Moy, MD, PhD

Dr. Moy practices at Columbia University Irving Medical Center in New York, New York.

Dr. Moy's NPI, 1164816005, was assigned on March 27, 2015. Dr. Moy graduated from Perelman School of Medicine - Philadelphia in 2015. Dr. Moy holds New York license 287759.

Dr. Moy's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Moy's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Moy is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Moy to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moy practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Moy's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Moy is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Moy's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists colorectal cancer among the conditions Dr. Moy treats.

CMS data shows 449 Medicare services from Dr. Moy across 5 procedure codes in 2024, for 108 Medicare patients. Medicare paid $43,898 for them.

CMS counts 108 Medicare patients who saw Dr. Moy in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Moy's median patient age at 70, with 33% women.

In 2024, Dr. Moy wrote 134 Medicare Part D claims for 34 patients. 71% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $161 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Moy for performance year 2024, reported through an alternative payment model (APM). Dr. Moy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Moy as offering telehealth.

Dmand AI links 39 papers to Dr. Moy, published from 2008 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Stomach Neoplasms, Esophageal Neoplasms and Adenocarcinoma. Dr. Moy has published most often in Cancer Chemother Pharmacol. Dr. Moy's most frequent co-authors are Yelena Y. Janjigian, MD, David H. Ilson, MD and Geoffrey Yuyat Ku, MD.

Dmand AI links Dr. Moy to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Stomach Neoplasms and Stomach Diseases.

CMS Open Payments shows 45 general payments to Dr. Moy from 12 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 79% of the total. Bristol-Myers Squibb Company paid the most, $7,927.

Dmand AI lists 2 awards for Dr. Moy, most recently Robert Black Fellow Award in 2021.

Dr. Moy graduated from Perelman School of Medicine - Philadelphia in 2015.

Dr. Moy is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.